Skip to main content

Advertisement

SpringerLink
Log in

Cellular and viral oncogenes: the key to unlocking unknowns of Kaposi’s sarcoma-associated herpesvirus pathogenesis

  • Review
  • Published:
Archives of Virology Aims and scope Submit manuscript

Abstract

Oncogenic viruses carry an extensive arsenal of oncogenes for hijacking cellular pathways. Notably, variations in oncogenes among tumor-producing viruses give rise to different mechanisms for cellular transformation. Specifically, Kaposi’s sarcoma-associated herpesvirus (KSHV) is an oncogenic virus able to infect and transform a variety of cell types. The oncogenicity of KSHV disseminates from the virus’ ability to induce and encode a wide variety of both cellular and viral oncogenes. Such an array of cellular and viral oncogenes enables KSHV to induce the malignant phenotype of a KSHV-associated cancer. Evolutionarily, KSHV has acquired many oncogenic homologues capable of inducing cell proliferation, cell differentiation, cell survival, and immune evasion. Integration between inducing and encoding oncogenes plays a vital role in KSHV pathogenicity. KSHV is alleged to harbor the highest number of potential oncogenes by which a virus promotes cellular transformation and malignancy. Many KSHV inducing/encoding oncogenes are mainly expressed during the latent phase of KSHV infection, a period required for virus establishment of malignant cellular transformation. Elucidation of the exact mechanism(s) by which oncogenes promote KSHV pathogenicity would not only give rise to potential novel therapeutic targets/drugs but would also add to our understanding of cancer biology. The scope of this review is to examine the roles of the most important cellular and viral oncogenes involved in KSHV pathogenicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Abere B, Schulz TF (2016) KSHV non-structural membrane proteins involved in the activation of intracellular signaling pathways and the pathogenesis of Kaposi’s sarcoma. Curr Opin Virol 20:11–19

    Article  PubMed  CAS  Google Scholar 

  2. Ajiro M, Zheng ZM (2014) Oncogenes and RNA splicing of human tumor viruses. Emerg Microbes Infect 3:e63

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Akula SM, Ford PW, Whitman AG, Hamden KE, Shelton JG, McCubrey JA (2004) Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection. Oncogene 23:5227–5241

    Article  PubMed  CAS  Google Scholar 

  4. An J, Sun Y, Sun R, Rettig MB (2003) Kaposi’s sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene 22:3371–3385

    Article  PubMed  CAS  Google Scholar 

  5. Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, Tosato G (1999) Angiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93:4034–4043

    PubMed  CAS  Google Scholar 

  6. Arias C, Weisburd B, Stern-Ginossar N, Mercier A, Madrid AS, Bellare P, Holdorf M, Weissman JS, Ganem D (2014) KSHV 2.0: a comprehensive annotation of the Kaposi’s sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features. PLoS Pathog 10:e1003847

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, Dias S, Silverstein RL, Rafii S, Mesri EA (2003) Kaposi’s sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell 3:131–143

    Article  PubMed  CAS  Google Scholar 

  8. Ballestas ME, Chatis PA, Kaye KM (1999) Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284:641–644

    Article  PubMed  CAS  Google Scholar 

  9. Ballon G, Chen K, Perez R, Tam W, Cesarman E (2011) Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice. J Clin Invest 121:1141–1153

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Baresova P, Pitha PM, Lubyova B (2013) Distinct roles of Kaposi’s sarcoma-associated herpesvirus-encoded viral interferon regulatory factors in inflammatory response and cancer. J Virol 87:9398–9410

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Bieleski L, Talbot SJ (2001) Kaposi’s sarcoma-associated herpesvirus vCyclin open reading frame contains an internal ribosome entry site. J Virol 75:1864–1869

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Bishop JM (1991) Molecular themes in oncogenesis. Cell 64:235–248

    Article  PubMed  CAS  Google Scholar 

  13. Bogenberger J, Whatcott C, Hansen N, Delman D, Shi CX, Kim W, Haws H, Soh K, Lee YS, Peterson P, Siddiqui-Jain A, Weitman S, Stewart K, Bearss D, Mesa R, Warner S, Tibes R (2017) Combined venetoclax and alvocidib in acute myeloid leukemia. Oncotarget 8:107206–107222

    Article  PubMed  PubMed Central  Google Scholar 

  14. Boissan M, Feger F, Guillosson JJ, Arock M (2000) c-Kit and c-kit mutations in mastocytosis and other hematological diseases. J Leukoc Biol 67:135–148

    Article  PubMed  CAS  Google Scholar 

  15. Bottero V, Sharma-Walia N, Kerur N, Paul AG, Sadagopan S, Cannon M, Chandran B (2009) Kaposi sarcoma-associated herpes virus (KSHV) G protein-coupled receptor (vGPCR) activates the ORF50 lytic switch promoter: a potential positive feedback loop for sustained ORF50 gene expression. Virology 392:34–51

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Bowser BS, DeWire SM, Damania B (2002) Transcriptional regulation of the K1 gene product of Kaposi’s sarcoma-associated herpesvirus. J Virol 76:12574–12583

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Brison O (1993) Gene amplification and tumor progression. Biochim Biophys Acta 1155:25–41

    PubMed  CAS  Google Scholar 

  18. Broecker F, Hardt C, Herwig R, Timmermann B, Kerick M, Wunderlich A, Schweiger MR, Borsig L, Heikenwalder M, Lehrach H, Moelling K (2016) Transcriptional signature induced by a C-terminal c-Src mutant in a human breast cell line. FEBS J 283:1669–1688

    Article  PubMed  CAS  Google Scholar 

  19. Brown MT, Cooper JA (1996) Regulation, substrates and functions of src. Biochim Biophys Acta 1287:121–149

    PubMed  Google Scholar 

  20. Cai Q, Verma SC, Lu J, Robertson ES (2010) Molecular biology of Kaposi’s sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res 78:87–142

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Cai Q, Xiao B, Si H, Cervini A, Gao J, Lu J, Upadhyay SK, Verma SC, Robertson ES (2012) Kaposi’s sarcoma herpesvirus upregulates Aurora A expression to promote p53 phosphorylation and ubiquitylation. PLoS Pathog 8:e1002566

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Cao Y, Minhas V, Tan X, Huang J, Wang B, Zhu M, Gao Y, Zhao T, Yang L, Wood C (2014) High prevalence of early childhood infection by Kaposi’s sarcoma-associated herpesvirus in a minority population in China. Clin Microbiol Infect 20:475–481

    Article  PubMed  CAS  Google Scholar 

  23. Carroll PA, Kenerson HL, Yeung RS, Lagunoff M (2006) Latent Kaposi’s sarcoma-associated herpesvirus infection of endothelial cells activates hypoxia-induced factors. J Virol 80:10802–10812

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Cavallin LE, Goldschmidt-Clermont P, Mesri EA (2014) Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi’s sarcoma associated with HIV/AIDS. PLoS Pathog 10:e1004154

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Cesarman E, Nador RG, Bai F, Bohenzky RA, Russo JJ, Moore PS, Chang Y, Knowles DM (1996) Kaposi’s sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi’s sarcoma and malignant lymphoma. J Virol 70:8218–8223

    PubMed  PubMed Central  CAS  Google Scholar 

  26. Cha S, Choe J, Seo T (2016) vIRF3 encoded by Kaposi’s sarcoma-associated herpesvirus inhibits T-cell factor-dependent transcription via a CREB-binding protein-interaction motif. Biochem Biophys Res Commun 479:697–702

    Article  PubMed  CAS  Google Scholar 

  27. Chaft JE, Arcila ME, Paik PK, Lau C, Riely GJ, Pietanza MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M, Kris MG (2012) Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 11:485–491

    Article  PubMed  CAS  Google Scholar 

  28. Chandran B (2010) Early events in Kaposi’s sarcoma-associated herpesvirus infection of target cells. J Virol 84:2188–2199

    Article  PubMed  CAS  Google Scholar 

  29. Chandriani S, Ganem D (2010) Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi’s sarcoma-associated herpesvirus. J Virol 84:5565–5573

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Chang Y, Moore PS, Talbot SJ, Boshoff CH, Zarkowska T, Godden K, Paterson H, Weiss RA, Mittnacht S (1996) Cyclin encoded by KS herpesvirus. Nature 382:410

    Article  PubMed  CAS  Google Scholar 

  31. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59:561–574

    Article  PubMed  CAS  Google Scholar 

  32. Chaudhary PM, Jasmin A, Eby MT, Hood L (1999) Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene 18:5738–5746

    Article  PubMed  CAS  Google Scholar 

  33. Cheng EH, Nicholas J, Bellows DS, Hayward GS, Guo HG, Reitz MS, Hardwick JM (1997) A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci USA 94:690–694

    Article  PubMed  CAS  Google Scholar 

  34. Chiou CJ, Poole LJ, Kim PS, Ciufo DM, Cannon JS, ap Rhys CM, Alcendor DJ, Zong JC, Ambinder RF, Hayward GS (2002) Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi’s sarcoma-associated herpesvirus. J Virol 76:3421–3439

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Chmura JC, Herold K, Ruffin A, Atuobi T, Fabiyi Y, Mitchell AE, Choi YB, Ehrlich ES (2017) The Itch ubiquitin ligase is required for KSHV RTA induced vFLIP degradation. Virology 501:119–126

    Article  PubMed  CAS  Google Scholar 

  36. Choi YB, Nicholas J (2008) Autocrine and paracrine promotion of cell survival and virus replication by human herpesvirus 8 chemokines. J Virol 82:6501–6513

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Coffin JM (1976) Genes responsible for transformation by avian RNA tumor viruses. Cancer Res 36:4282–4288

    PubMed  CAS  Google Scholar 

  38. Cohen A, Brodie C, Sarid R (2006) An essential role of ERK signalling in TPA-induced reactivation of Kaposi’s sarcoma-associated herpesvirus. J Gen Virol 87:795–802

    Article  PubMed  CAS  Google Scholar 

  39. Croce CM (2008) Oncogenes and cancer. N Engl J Med 358:502–511

    Article  PubMed  CAS  Google Scholar 

  40. Cuconati A, White E (2002) Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. Genes Dev 16:2465–2478

    Article  PubMed  CAS  Google Scholar 

  41. Cunningham C, Barnard S, Blackbourn DJ, Davison AJ (2003) Transcription mapping of human herpesvirus 8 genes encoding viral interferon regulatory factors. J Gen Virol 84:1471–1483

    Article  PubMed  CAS  Google Scholar 

  42. Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19:1–11

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Dang CV (2012) MYC on the path to cancer. Cell 149:22–35

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Deeks ED (2016) Venetoclax: first global approval. Drugs 76:979–987

    Article  PubMed  CAS  Google Scholar 

  45. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla-Favera R (2007) Non-transcriptional control of DNA replication by c-Myc. Nature 448:445–451

    Article  PubMed  CAS  Google Scholar 

  46. Faris M, Ensoli B, Kokot N, Nel AE (1998) Inflammatory cytokines induce the expression of basic fibroblast growth factor (bFGF) isoforms required for the growth of Kaposi’s sarcoma and endothelial cells through the activation of AP-1 response elements in the bFGF promoter. Aids 12:19–27

    Article  PubMed  CAS  Google Scholar 

  47. Fernandez-Figueras MT, Puig L, Fernandez-Vasalo A, Esquius M, Montero MA, Ariza A (2000) Immunohistochemical detection of Bcl-2 in Kaposi’s sarcoma lesions varies according to histopathologic stage, whereas expression of Bcl-x and Mcl-1 differs according to human immunodeficiency virus serologic status of patients. Mod Pathol 13:438–445

    Article  PubMed  CAS  Google Scholar 

  48. Field N, Low W, Daniels M, Howell S, Daviet L, Boshoff C, Collins M (2003) KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci 116:3721–3728

    Article  PubMed  CAS  Google Scholar 

  49. Filippakis H, Spandidos DA, Sourvinos G (2010) Herpesviruses: hijacking the Ras signaling pathway. Biochim Biophys Acta 1803:777–785

    Article  PubMed  CAS  Google Scholar 

  50. Ford PW, Bryan BA, Dyson OF, Weidner DA, Chintalgattu V, Akula SM (2006) Raf/MEK/ERK signalling triggers reactivation of Kaposi’s sarcoma-associated herpesvirus latency. J Gen Virol 87:1139–1144

    Article  PubMed  CAS  Google Scholar 

  51. Frixa T, Donzelli S, Blandino G (2015) Oncogenic MicroRNAs: key players in malignant transformation. Cancers (Basel) 7:2466–2485

    Article  CAS  Google Scholar 

  52. Fu J, Liu Y, Wang X, Yuan B, Zhang Y (2017) Role of DHX33 in c-Myc-induced cancers. Carcinogenesis 38:649–660

    Article  PubMed  CAS  Google Scholar 

  53. Gallo A, Lampe M, Gunther T, Brune W (2017) The viral Bcl-2 homologs of Kaposi’s sarcoma-associated herpesvirus and rhesus rhadinovirus share an essential role for viral replication. J Virol 91:e01875-16

    Article  PubMed  PubMed Central  Google Scholar 

  54. Gan HK, Seruga B, Knox JJ (2009) Sunitinib in solid tumors. Expert Opin Investig Drugs 18:821–834

    Article  PubMed  CAS  Google Scholar 

  55. Ganem D (2010) KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 120:939–949

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Ganesh S, Shui X, Craig K, Koser M, Chopda GR, Cyr WA, Lai C, Dudek H, Wang W, Brown B, Abrams M (2018) β-catenin mRNA silencing and MEK inhibition display synergistic efficacy in preclinical tumor models. Mol Cancer Ther 17:544–553

    Article  PubMed  CAS  Google Scholar 

  57. Gao J, Cai Q, Lu J, Jha HC, Robertson ES (2011) Upregulation of cellular Bcl-2 by the KSHV encoded RTA promotes virion production. PLoS One 6:e23892

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Gao SJ, Boshoff C, Jayachandra S, Weiss RA, Chang Y, Moore PS (1997) KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 15:1979–1985

    Article  PubMed  CAS  Google Scholar 

  59. Gelgor A, Kalt I, Bergson S, Brulois KF, Jung JU, Sarid R (2015) Viral Bcl-2 encoded by the Kaposi’s sarcoma-associated herpesvirus is vital for virus reactivation. J Virol 89:5298–5307

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Giffin L, Damania B (2014) KSHV: pathways to tumorigenesis and persistent infection. Adv Virus Res 88:111–159

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Giffin L, West JA, Damania B (2015) Kaposi’s sarcoma-associated herpesvirus interleukin-6 modulates endothelial cell movement by upregulating cellular genes involved in migration. MBio 6:e01499–e01515

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Gramolelli S, Schulz TF (2015) The role of Kaposi sarcoma-associated herpesvirus in the pathogenesis of Kaposi sarcoma. J Pathol 235:368–380

    Article  PubMed  CAS  Google Scholar 

  63. Grundhoff A, Ganem D (2001) Mechanisms governing expression of the v-FLIP gene of Kaposi’s sarcoma-associated herpesvirus. J Virol 75:1857–1863

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Guasparri I, Keller SA, Cesarman E (2004) KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 199:993–1003

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Guislain A, Gadiot J, Kaiser A, Jordanova ES, Broeks A, Sanders J, van Boven H, de Gruijl TD, Haanen JB, Bex A, Blank CU (2015) Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer Immunol Immunother 64:1241–1250

    Article  PubMed  CAS  Google Scholar 

  66. Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692–1703

    Article  PubMed  CAS  Google Scholar 

  67. Hu D, Wang V, Yang M, Abdullah S, Davis DA, Uldrick TS, Polizzotto MN, Veeranna RP, Pittaluga S, Tosato G, Yarchoan R (2015) Induction of Kaposi’s sarcoma-associated herpesvirus-encoded viral interleukin-6 by X-box binding protein 1. J Virol 90:368–378

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  68. Hussein HA, Walker LR, Abdel-Raouf UM, Desouky SA, Montasser AK, Akula SM (2015) Beyond RGD: virus interactions with integrins. Arch Virol 160:2669–2681

    Article  PubMed  CAS  Google Scholar 

  69. Hussein TM, El-Sabaa BM, Hanafy NF (2012) Evaluation of c-kit expression in classic Kaposi’s sarcoma in a cohort of Egyptian patients. J Egypt Natl Canc Inst 24:1–6

    Article  PubMed  Google Scholar 

  70. Hwang SW, Kim D, Jung JU, Lee HR (2017) KSHV-encoded viral interferon regulatory factor 4 (vIRF4) interacts with IRF7 and inhibits interferon alpha production. Biochem Biophys Res Commun 486:700–705

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Irby RB, Yeatman TJ (2000) Role of Src expression and activation in human cancer. Oncogene 19:5636–5642

    Article  PubMed  CAS  Google Scholar 

  72. Jacobs SR, Damania B (2011) The viral interferon regulatory factors of KSHV: immunosuppressors or oncogenes? Front Immunol 2:19

    Article  PubMed  PubMed Central  Google Scholar 

  73. Jaraiz-Rodriguez M, Tabernero MD, Gonzalez-Tablas M, Otero A, Orfao A, Medina JM, Tabernero A (2017) A short region of Connexin43 reduces human glioma stem cell migration, invasion, and survival through Src, PTEN, and FAK. Stem cell Reports 9:451–463

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Jensen KK, Manfra DJ, Grisotto MG, Martin AP, Vassileva G, Kelley K, Schwartz TW, Lira SA (2005) The human herpes virus 8-encoded chemokine receptor is required for angioproliferation in a murine model of Kaposi’s sarcoma. J Immunol 174:3686–3694

    Article  PubMed  CAS  Google Scholar 

  75. Jones T, Ramos da Silva S, Bedolla R, Ye F, Zhou F, Gao SJ (2014) Viral cyclin promotes KSHV-induced cellular transformation and tumorigenesis by overriding contact inhibition. Cell Cycle 13:845–858

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Just WW, Peranen J (2016) Small GTPases in peroxisome dynamics. Biochim Biophys Acta 1863:1006–1013

    Article  PubMed  CAS  Google Scholar 

  77. Kandemir NO, Gun BD, Bahadir B, Yurdakan G, Ozdemir N, Karadayi N, Ozdamar SO (2010) c-Kit (CD117) expression in classic Kaposi’s sarcoma. Clin Exp Dermatol 35:525–530

    Article  PubMed  CAS  Google Scholar 

  78. Kerr DA, Busarla SVP, Gimbel DC, Sohani AR, Nazarian RM (2017) mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi sarcoma. Hum Pathol 65:157–165

    Article  PubMed  CAS  Google Scholar 

  79. Kiss E, Mirzahosseini A, Hubert A, Ambrus A, Orfi L, Horvath P (2017) DNA binding of sunitinib: Spectroscopic evidence via circular dichroism and nuclear magnetic resonance. J Pharm Biomed Anal 150:355–361

    Article  PubMed  CAS  Google Scholar 

  80. Kissel M, Berndt S, Fiebig L, Kling S, Ji Q, Gu Q, Lang T, Hafner FT, Teufel M, Zopf D (2017) Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma. Oncotarget 8:107096–107108

    Article  PubMed  PubMed Central  Google Scholar 

  81. Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M, Reed JC (2008) Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 111:3211–3219

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Koon HB, Krown SE, Lee JY, Honda K, Rapisuwon S, Wang Z, Aboulafia D, Reid EG, Rudek MA, Dezube BJ, Noy A (2014) Phase II trial of imatinib in AIDS-associated Kaposi’s sarcoma: AIDS malignancy consortium protocol 042. J Clin Oncol 32:402–408

    Article  PubMed  CAS  Google Scholar 

  83. Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D, Cuddy M, Huang X, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, Jassem J, Meinhold-Heerlein I, Duffy MJ, Schimmer AD, Tsao M, Brown E, Sawyers A, Andreeff M, Mercola D, Krajewski S, Reed JC (2008) Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res 14:3011–3021

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  84. Krygowska AA, Castellano E (2018) PI3K: a crucial piece in the RAS signaling puzzle. Cold Spring Harbor Perspect Med 8:a031450

    Article  Google Scholar 

  85. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867–1876

    Article  PubMed  CAS  Google Scholar 

  86. Lee HR, Doganay S, Chung B, Toth Z, Brulois K, Lee S, Kanketayeva Z, Feng P, Ha T, Jung JU (2014) Kaposi’s sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets expression of cellular IRF4 and the Myc gene to facilitate lytic replication. J Virol 88:2183–2194

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  87. Lee LA, Resar LM, Dang CV (1995) Cell density and paradoxical transcriptional properties of c-Myc and Max in cultured mouse fibroblasts. J Clin Invest 95:900–904

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, Belmont LD, Nimmer P, Xiao Y, Ma XM, Lowes KN, Kovar P, Chen J, Jin S, Smith M, Xue J, Zhang H, Oleksijew A, Magoc TJ, Vaidya KS, Albert DH, Tarrant JM, La N, Wang L, Tao ZF, Wendt MD, Sampath D, Rosenberg SH, Tse C, Huang DC, Fairbrother WJ, Elmore SW, Souers AJ (2015) Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 7:279ra240

    Article  CAS  Google Scholar 

  89. Li M, Lee H, Yoon DW, Albrecht JC, Fleckenstein B, Neipel F, Jung JU (1997) Kaposi’s sarcoma-associated herpesvirus encodes a functional cyclin. J Virol 71:1984–1991

    PubMed  PubMed Central  CAS  Google Scholar 

  90. Liang D, Hu H, Li S, Dong J, Wang X, Wang Y, He L, He Z, Gao Y, Gao SJ, Lan K (2014) Oncogenic herpesvirus KSHV Hijacks BMP-Smad1-Id signaling to promote tumorigenesis. PLoS Pathog 10:e1004253

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. Lugowska I, Kosela-Paterczyk H, Kozak K, Rutkowski P (2015) Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther 8:2251–2259

    PubMed  PubMed Central  CAS  Google Scholar 

  92. Malaise M, Steinbach D, Corbacioglu S (2009) Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep 4:77–82

    Article  PubMed  Google Scholar 

  93. Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3:459–465

    Article  PubMed  CAS  Google Scholar 

  94. Martin D, Gutkind JS (2008) Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene 27(Suppl 2):S31–S42

    Article  PubMed  CAS  Google Scholar 

  95. Martin D, Galisteo R, Molinolo AA, Wetzker R, Hirsch E, Gutkind JS (2011) PI3Kgamma mediates kaposi’s sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. Cancer Cell 19:805–813

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  96. McGee JH, Shim SY, Lee SJ, Swanson PK, Jiang Y, Durney MA, Verdine GL (2018) Exceptionally high-affinity Ras binders that remodel its effector domain. J Biol Chem 293:3265–3280

    Article  PubMed  CAS  Google Scholar 

  97. Mesri EA, Feitelson MA, Munger K (2014) Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 15:266–282

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  98. Meyer N, Penn LZ (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8:976–990

    Article  PubMed  CAS  Google Scholar 

  99. Miles SA, Rezai AR, Salazar-Gonzalez JF, Vander Meyden M, Stevens RH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T et al (1990) AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 87:4068–4072

    Article  PubMed  CAS  Google Scholar 

  100. Mitelman F (2000) Recurrent chromosome aberrations in cancer. Mutat Res 462:247–253

    Article  PubMed  CAS  Google Scholar 

  101. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y, Li Y, Ray PE, Gutkind JS (2003) Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3:23–36

    Article  PubMed  CAS  Google Scholar 

  102. Moore PS, Chang Y (2010) Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 10:878–889

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Munshi N, Groopman JE, Gill PS, Ganju RK (2000) c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi’s sarcoma cells. J Immunol 164:1169–1174

    Article  PubMed  CAS  Google Scholar 

  104. Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar AP (2009) Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett 283:143–151

    Article  PubMed  CAS  Google Scholar 

  105. Pantanowitz L, Schwartz EJ, Dezube BJ, Kohler S, Dorfman RF, Tahan SR (2005) C-Kit (CD117) expression in AIDS-related, classic, and African endemic Kaposi sarcoma. Appl Immunohistochem Mol Morphol 13:162–166

    Article  PubMed  CAS  Google Scholar 

  106. Pozharskaya VP, Weakland LL, Zimring JC, Krug LT, Unger ER, Neisch A, Joshi H, Inoue N, Offermann MK (2004) Short duration of elevated vIRF-1 expression during lytic replication of human herpesvirus 8 limits its ability to block antiviral responses induced by alpha interferon in BCBL-1 cells. J Virol 78:6621–6635

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  107. Prakash O, Tang ZY, Peng X, Coleman R, Gill J, Farr G, Samaniego F (2002) Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene. J Natl Cancer Inst 94:926–935

    Article  PubMed  CAS  Google Scholar 

  108. Purushothaman P, Uppal T, Verma SC (2015) Molecular biology of KSHV lytic reactivation. Viruses 7:116–153

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  109. Purushothaman P, Uppal T, Sarkar R, Verma SC (2016) KSHV-mediated angiogenesis in tumor progression. Viruses 8:E198

    Article  PubMed  CAS  Google Scholar 

  110. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30–39

    Article  PubMed  CAS  Google Scholar 

  111. Rosean TR, Holman CJ, Tompkins VS, Jing X, Krasowski MD, Rose-John S, Janz S (2016) KSHV-encoded vIL-6 collaborates with deregulated c-Myc to drive plasmablastic neoplasms in mice. Blood Cancer J 6:e398

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  112. Roskoski R Jr (2005) Signaling by kit protein-tyrosine kinase—the stem cell factor receptor. Biochem Biophys Res Commun 337:1–13

    Article  PubMed  CAS  Google Scholar 

  113. Sakakibara S, Tosato G (2011) Viral interleukin-6: role in Kaposi’s sarcoma-associated herpesvirus: associated malignancies. J Interferon Cytokine Res 31:791–801

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  114. Sarid R, Sato T, Bohenzky RA, Russo JJ, Chang Y (1997) Kaposi’s sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 3:293–298

    Article  PubMed  CAS  Google Scholar 

  115. Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS (1998) Transcription mapping of the Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol 72:1005–1012

    PubMed  PubMed Central  CAS  Google Scholar 

  116. Seo T, Lee D, Lee B, Chung JH, Choe J (2000) Viral interferon regulatory factor 1 of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) binds to, and inhibits transactivation of, CREB-binding protein. Biochem Biophys Res Commun 270:23–27

    Article  PubMed  CAS  Google Scholar 

  117. Shin YC, Nakamura H, Liang X, Feng P, Chang H, Kowalik TF, Jung JU (2006) Inhibition of the ATM/p53 signal transduction pathway by Kaposi’s sarcoma-associated herpesvirus interferon regulatory factor 1. J Virol 80:2257–2266

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  118. Sin SH, Kim Y, Eason A, Dittmer DP (2015) KSHV latency locus cooperates with Myc to drive lymphoma in mice. PLoS Pathog 11:e1005135

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  119. Soto D, Song C, McLaughlin-Drubin ME (2017) Epigenetic alterations in human papillomavirus-associated cancers. Viruses 9:E248

    Article  PubMed  CAS  Google Scholar 

  120. Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, Rosean TR, Klapper W, Tosato G, Janz S, Scheller J, Rose-John S (2012) HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood 119:5173–5181

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  121. Swanton C, Mann DJ, Fleckenstein B, Neipel F, Peters G, Jones N (1997) Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390:184–187

    Article  PubMed  CAS  Google Scholar 

  122. Takahashi RH, Choo EF, Ma S, Wong S, Halladay J, Deng Y, Rooney I, Gates M, Hop CE, Khojasteh SC, Dresser MJ, Musib L (2016) Absorption, metabolism, excretion, and the contribution of intestinal metabolism to the oral disposition of [14C] cobimetinib, a MEK inhibitor, in humans. Drug Metab Dispos 44:28–39

    Article  PubMed  CAS  Google Scholar 

  123. Tamura T, Yanai H, Savitsky D, Taniguchi T (2008) The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 26:535–584

    Article  PubMed  CAS  Google Scholar 

  124. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J (1997) Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517–521

    Article  PubMed  CAS  Google Scholar 

  125. Trop-Steinberg S, Azar Y (2018) Is Myc an important biomarker? Myc expression in immune disorders and cancer. Am J Med Sci 355:67–75

    Article  PubMed  Google Scholar 

  126. Uldrick TS, Whitby D (2011) Update on KSHV epidemiology, Kaposi sarcoma pathogenesis, and treatment of Kaposi sarcoma. Cancer Lett 305:150–162

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  127. Veettil MV, Sharma-Walia N, Sadagopan S, Raghu H, Sivakumar R, Naranatt PP, Chandran B (2006) RhoA-GTPase facilitates entry of Kaposi’s sarcoma-associated herpesvirus into adherent target cells in a Src-dependent manner. J Virol 80:11432–11446

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  128. Verschuren EW, Jones N, Evan GI (2004) The cell cycle and how it is steered by Kaposi’s sarcoma-associated herpesvirus cyclin. J Gen Virol 85:1347–1361

    Article  PubMed  CAS  Google Scholar 

  129. Wang F, Guo Y, Li W, Lu C, Yan Q (2017) Generation of a KSHV K13 deletion mutant for vFLIP function study. J Med Virol

  130. Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B (2006) Immortalization of primary endothelial cells by the K1 protein of Kaposi’s sarcoma-associated herpesvirus. Cancer Res 66:3658–3666

    Article  PubMed  CAS  Google Scholar 

  131. Wang X, He Z, Xia T, Li X, Liang D, Lin X, Wen H, Lan K (2014) Latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus promotes angiogenesis through targeting notch signaling effector Hey1. Cancer Res 74:2026–2037

    Article  PubMed  CAS  Google Scholar 

  132. Wheeler DL, Iida M, Dunn EF (2009) The role of Src in solid tumors. Oncologist 14:667–678

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  133. Widmer I, Wernli M, Bachmann F, Gudat F, Cathomas G, Erb P (2002) Differential expression of viral Bcl-2 encoded by Kaposi’s sarcoma-associated herpesvirus and human Bcl-2 in primary effusion lymphoma cells and Kaposi’s sarcoma lesions. J Virol 76:2551–2556

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  134. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109

    Article  PubMed  CAS  Google Scholar 

  135. Wu H, Liu L, Xiao J, Chi M, Qu Y, Feng H (2015) Glycosylation of KSHV encoded vGPCR functions in its signaling and tumorigenicity. Viruses 7:1627–1641

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  136. Xiao B, Verma SC, Cai Q, Kaul R, Lu J, Saha A, Robertson ES (2010) Bub1 and CENP-F can contribute to Kaposi’s sarcoma-associated herpesvirus genome persistence by targeting LANA to kinetochores. J Virol 84:9718–9732

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  137. Xu L, Xie Q, Qi L, Wang C, Xu N, Liu W, Yu Y, Li S, Xu Y (2018) Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2+ signaling in SKOV3 cells. Oncol Rep 39:985–992

    PubMed  Google Scholar 

  138. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A (1987) Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. Embo J 6:3341–3351

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  139. Ye FC, Zhou FC, Yoo SM, Xie JP, Browning PJ, Gao SJ (2004) Disruption of Kaposi’s sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. J Virol 78:11121–11129

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  140. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4:470–480

    Article  PubMed  CAS  Google Scholar 

  141. Yip KW, Reed JC (2008) Bcl-2 family proteins and cancer. Oncogene 27:6398–6406

    Article  PubMed  CAS  Google Scholar 

  142. Yoo SM, Zhou FC, Ye FC, Pan HY, Gao SJ (2005) Early and sustained expression of latent and host modulating genes in coordinated transcriptional program of KSHV productive primary infection of human primary endothelial cells. Virology 343:47–64

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  143. Yoshida N, Doisaki S, Kojima S (2012) Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations. Paediatr Drugs 14:157–163

    Article  PubMed  Google Scholar 

  144. Yu F, Harada JN, Brown HJ, Deng H, Song MJ, Wu TT, Kato-Stankiewicz J, Nelson CG, Vieira J, Tamanoi F, Chanda SK, Sun R (2007) Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus. PLoS Pathog 3:e44

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  145. Zachos G, Spandidos DA (1998) Transcriptional regulation of the c-H-ras1 gene by the P53 protein is implicated in the development of human endometrial and ovarian tumours. Oncogene 16:3013–3017

    Article  PubMed  CAS  Google Scholar 

  146. Zhang E, Cotton VE, Hidalgo-Bravo A, Huang Y, Bell AJ, Jarrett RF, Wilkie GS, Davison AJ, Nacheva EP, Siebert R, Majid A, Kelpanides I, Jayne S, Dyer MJ, Royle NJ (2016) HHV-8-unrelated primary effusion-like lymphoma associated with clonal loss of inherited chromosomally-integrated human herpesvirus-6A from the telomere of chromosome 19q. Sci Rep 6:22730

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  147. Zhang P, Kawakami H, Liu W, Zeng X, Strebhardt K, Tao K, Huang S, Sinicrope FA (2017) Targeting CDK1 and MEK/ERK overcomes apoptotic resistance in BRAF mutated human colorectal cancer. Mol Cancer Res

  148. Zhang X, Zhang Y (2015) Bladder cancer and genetic mutations. Cell Biochem Biophys 73:65–69

    Article  PubMed  CAS  Google Scholar 

  149. Zhi H, Zahoor MA, Shudofsky AM, Giam CZ (2015) KSHV vCyclin counters the senescence/G1 arrest response triggered by NF-kappaB hyperactivation. Oncogene 34:496–505

    Article  PubMed  CAS  Google Scholar 

  150. Zhong W, Wang H, Herndier B, Ganem D (1996) Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci USA 93:6641–6646

    Article  PubMed  CAS  Google Scholar 

  151. Zhu X, Guo Y, Yao S, Yan Q, Xue M, Hao T, Zhou F, Zhu J, Qin D, Lu C (2014) Synergy between Kaposi’s sarcoma-associated herpesvirus (KSHV) vIL-6 and HIV-1 Nef protein in promotion of angiogenesis and oncogenesis: role of the AKT signaling pathway. Oncogene 33:1986–1996

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, 27834, USA

    Hosni A. M. Hussein, Ikenna B. Okafor, Lia R. Walker & Shaw M. Akula

  2. Faculty of Science, Al Azhar University, Assiut Branch, Assiut, 71524, Egypt

    Usama M. Abdel-Raouf

Authors
  1. Hosni A. M. Hussein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ikenna B. Okafor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lia R. Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Usama M. Abdel-Raouf
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shaw M. Akula
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaw M. Akula.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Handling Editor: Zhongjie Shi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hussein, H.A.M., Okafor, I.B., Walker, L.R. et al. Cellular and viral oncogenes: the key to unlocking unknowns of Kaposi’s sarcoma-associated herpesvirus pathogenesis. Arch Virol 163, 2633–2643 (2018). https://doi.org/10.1007/s00705-018-3918-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-018-3918-3

Search

Navigation